Dominant-negative mutation of p53 tumor suppressor gene in endometrial carcinoma

Gynecologic Oncology

Volumn 83, Issue 3, 2001, Pages 485-490

  Sakuragi, Noriaki ^a   Hirai, Atsuko ^a   Tada, Mitsuhiro ^a   Yamada, Hideto ^a   Yamamoto, Ritsu ^a   Fujimoto, Seiichiro ^a   Moriuchi, Tetsuya ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

Author keywords

Dominant negative mutation; Endometrial carcinoma; p53; Serous adenocarcinoma; Yeast functional assay

Indexed keywords

PROTEIN P53;

ADENOCARCINOMA; ARTICLE; CARCINOGENESIS; CODON; CONTROLLED STUDY; DISEASE COURSE; DNA SEQUENCE; ENDOMETRIUM CARCINOMA; FEMALE; GENE INACTIVATION; GENE MUTATION; HOMOZYGOSITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; TRANSCRIPTION REGULATION; TUMOR SUPPRESSOR GENE;

EID: 0035209616     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.2001.6429     Document Type: Article

References (29)

1. Prognostic significance of serous and clear cell adenocarcinoma in surgically staged endometrial carcinoma
2. p53 overexpression and bcl-2 persistence in endometrial carcinoma: Comparison of papillary serous and endometrioid subtypes
3. Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers
4. Clinical implications of K-ras mutations in malignant epithelial tumors of the endometrium
5. The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma: Evidence of distinct molecular genetic pathways
6. Pathologic stage III endometrial carcinoma. Prognostic factors and patterns of recurrence
7. p53 in endometrial cancer and its putative precursors: Evidence for diverse pathways of tumorigenesis
8. p53: A transdominant regulator of transcription whose function is ablated by mutations occurring in human cancer
9. Dominant negative effect of a germ-line mutant p53: A step fostering tumorigenesis
10. A simple p53 functional assay for screening cell lines, blood, and tumors
11. High frequency of p53 mutations in human oral epithelial dysplasia and primary squamous cell carcinoma detected by yeast functional assay
12. Dominant-negative mutations of the tumor suppressor p53 relating to early onset of glioblastoma multiforme
13. Tumors of the uterine corpus and gestational trophoblastic disease
14. p53 immunostaining as a significant adjunct diagnostic method for uterine surface carcinoma. Precursor of uterine papillary serous carcinoma
15. Minimal uterine serous carcinoma. Diagnosis and clinicopathologic correlation
16. Establishment of a cell line of human endometrial adenocarcinoma in vitro
17. Establishment of human endometrial adenocarcinoma cell line containing estradiol-17β and progesterone receptors
18. Establishment of a new human endometrial adenocarcinoma cell line, Ishikawa cells, containing estrogen and progesterone receptors
19. Biologic characteristics of adenocarcinoma cell line (HOUA-I) and B-lymphoblastoid cell line (HOUA-II) established from the same tissue of endometrial adenocarcinoma
20. Establishment and characterization of human cell lines from a serous papillary adenocarcinoma of the endometrium
21. Reappraisal of p53 mutations in human malignant astrocytic neoplasms by p53 functional assay: Comparison with conventional structural analyses
22. Multiple methods of visualizing the yeast vacuole permit evaluation of its morphology and inheritance during the cell cycle
23. Distinct prognostic values of p53 mutations and loss of estrogen receptor and their cumulative effect in primary breast cancers
24. Decreased E-cadherin expression in endometrial carcinoma is associated with tumor dedifferentiation and deep myometrial invasion
25. Dominant-negative p53 mutations selected in yeast hit cancer hot spots
26. p53 gene mutations are common in uterine serous carcinoma and occur early in their pathogenesis
27. Mutant p53: Gain-of-function oncoproteins and wild-type p53 inactivators
28. Gain of function mutations in p53
29. Gain-of-function mutations in the tumor suppressor gene p53